Cargando…

19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA

Understanding the mechanisms behind melanoma brain metastasis, a disease that continues to portend a poor prognosis, will lead to the identification and development of novel drug targets. We previously identified PLEKHA5, a gene involved in brain development, as a novel molecule implicated in melano...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oria, Victor, Zhang, Hongyi, Zhu, Huifang, Deng, Gang, Zito, Christopher, Rane, Chetan, Zhang, Shenqi, Weiss, Sarah, Tran, Thuy, Adeniran, Adebowale, Zhang, Fanfan, Zhou, Jiangbing, Kluger, Yuval, Bosenberg, Marcus, Kluger, Harriet, Jilaveanu, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401364/ http://dx.doi.org/10.1093/noajnl/vdaa073.009

Ejemplares similares

Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma
por: Oria, Victor O., et al.
Publicado: (2022)

Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
por: Weiss, Sarah A., et al.
Publicado: (2020)

Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells
por: Tran, Thuy T., et al.
Publicado: (2021)

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
por: Shuch, Brian, et al.
Publicado: (2015)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
por: Baine, Marina K., et al.
Publicado: (2015)

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
por: Aziz, Saadia A, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

WW, PH and C-Terminal Domains Cooperate to Direct the Subcellular Localizations of PLEKHA5, PLEKHA6 and PLEKHA7
por: Sluysmans, Sophie, et al.
Publicado: (2021)

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
por: Damsky, William, et al.
Publicado: (2019)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma
por: Su, David, et al.
Publicado: (2023)

PLEKHA5, PLEKHA6, and PLEKHA7 bind to PDZD11 to target the Menkes ATPase ATP7A to the cell periphery and regulate copper homeostasis
por: Sluysmans, Sophie, et al.
Publicado: (2021)

Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
por: Tran, Thuy T., et al.
Publicado: (2019)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?
por: Su, David, et al.
Publicado: (2023)

Vascularity of primary and metastatic renal cell carcinoma specimens
por: Aziz, Saadia A, et al.
Publicado: (2013)

Characterizing disease states from topological properties of transcriptional regulatory networks
por: Tuck, David P, et al.
Publicado: (2006)

SIMVI reveals intrinsic and spatial-induced states in spatial omics data
por: Dong, Mingze, et al.
Publicado: (2023)

Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure
por: Qu, Rihao, et al.
Publicado: (2022)

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
por: Jilaveanu, L.B., et al.
Publicado: (2014)

[(11)C]Methionine and [(11)C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis
por: Tran, Thuy T., et al.
Publicado: (2020)

A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
por: Schoenfeld, David, et al.
Publicado: (2023)

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
por: Djureinovic, Dijana, et al.
Publicado: (2023)

Drug targets and predictive biomarkers in the management of metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2012)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases
por: Lu, Benjamin Y, et al.
Publicado: (2021)

PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma
por: Zhang, Wei, et al.
Publicado: (2023)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

64. AN ENT2-DEPENDENT, CELL-PENETRATING, AND DNA-DAMAGING LUPUS AUTOANTIBODY CROSSES THE BLOOD-BRAIN BARRIER TO TARGET BRAIN TUMORS
por: Rattray, Zahra, et al.
Publicado: (2020)

PLEKHA7 modulates epithelial tight junction barrier function
por: Paschoud, Serge, et al.
Publicado: (2014)

Origin and Evolution of the Multifaceted Adherens Junction Component Plekha7
por: Kourtidis, Antonis, et al.
Publicado: (2022)

Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic
por: Kluger, Dan M., et al.
Publicado: (2020)

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells
por: Zito, Christopher R., et al.
Publicado: (2012)

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten−/− melanoma
por: Scortegagna, Marzia, et al.
Publicado: (2013)

Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
por: Esposito, Andrew, et al.
Publicado: (2021)

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
por: Nadler, Yasmine, et al.
Publicado: (2008)

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
por: Parisi, Fabio, et al.
Publicado: (2010)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_am5k6kms8qg593alp53qv22dnc